Cost-Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study
View ORCID ProfileJosé Seijas-Amigo, M. José Mauriz-Montero, Pedro Suarez-Artime, Mónica Gayoso-Rey, View ORCID ProfileFrancisco Reyes-Santías, Ana Estany-Gestal, Antonia Casas-Martínez, Lara González-Freire, View ORCID ProfileAna Rodriguez-Vazquez, Natalia Pérez-Rodriguez, Laura Villaverde-Piñeiro, Concepción Castro-Rubinos, Esther Espino-Faisán, Octavio Cordova-Arevalo, Moisés Rodríguez-Mañero, View ORCID ProfileAlberto Cordero, José R. González-Juanatey, e Investigadores MEMOGAL
doi: https://doi.org/10.1101/2023.12.05.23299557
José Seijas-Amigo
1Cardiology Department. Complejo Hospitalario Universidad de Santiago de Compostela. Santiago de Compostela. Spain
2Fundación Instituto de Investigación Sanitaria de Santiago de Compostela (FIDIS). Spain
3Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain
PharmM. José Mauriz-Montero
4Pharmacy Department. Complejo Hospitalario Universitario A Coruña. Spain
PharmPedro Suarez-Artime
5Pharmacy Department. Complejo Hospitalario Universidad de Santiago de Compostela. Santiago de Compostela. Spain
PharmMónica Gayoso-Rey
6Pharmacy Department. Complejo Hospitalario Universitario de Vigo. Spain
PharmFrancisco Reyes-Santías
7Management Department, Complejo Hospitalario Universidad de Santiago de Compostela, Santiago de Compostela, Spain
PhDAna Estany-Gestal
2Fundación Instituto de Investigación Sanitaria de Santiago de Compostela (FIDIS). Spain
Pharm, PhDAntonia Casas-Martínez
8Pharmacy Department. Complejo Hospitalario Universitario de Ferrol. Spain
PharmLara González-Freire
9Pharmacy Department. Complejo Hospitalario Universitario de Pontevedra. Spain
PharmAna Rodriguez-Vazquez
10Pharmacy Department. Complejo Hospitalario Universitario de Ourense
PharmNatalia Pérez-Rodriguez
11Pharmacy Department. Complejo Hospitalario Universitario de Lugo
PharmLaura Villaverde-Piñeiro
12Pharmacy Department. Hospital Comarcal de Monforte. Spain
PharmConcepción Castro-Rubinos
13Pharmacy Department. Hospital Público da Mariña. Spain
PharmEsther Espino-Faisán
14Pharmacy Department. Hospital do Barbanza. Spain
PharmOctavio Cordova-Arevalo
15PEMEX, Universidade de Vigo, Spain
Msc.,BscMoisés Rodríguez-Mañero
1Cardiology Department. Complejo Hospitalario Universidad de Santiago de Compostela. Santiago de Compostela. Spain
3Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain
MD, PhDAlberto Cordero
3Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain
15PEMEX, Universidade de Vigo, Spain
16Cardiology Department. Hospital Universitario de San Juan. Alicante, Spain
MD, PhDJosé R. González-Juanatey
1Cardiology Department. Complejo Hospitalario Universidad de Santiago de Compostela. Santiago de Compostela. Spain
3Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain
MD, PhD, FESC, FACCData Availability
Availability of data and material (data transparency) In this article, we are committed to data transparency and availability of materials used in our research. The data and materials will be available on demand for readers interested in replicating or building upon our study. Interested parties can contact the corresponding author to request access to the data and materials. We will ensure that the requested information and materials are provided in a timely and complete manner.
Posted December 07, 2023.
Cost-Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study
José Seijas-Amigo, M. José Mauriz-Montero, Pedro Suarez-Artime, Mónica Gayoso-Rey, Francisco Reyes-Santías, Ana Estany-Gestal, Antonia Casas-Martínez, Lara González-Freire, Ana Rodriguez-Vazquez, Natalia Pérez-Rodriguez, Laura Villaverde-Piñeiro, Concepción Castro-Rubinos, Esther Espino-Faisán, Octavio Cordova-Arevalo, Moisés Rodríguez-Mañero, Alberto Cordero, José R. González-Juanatey, e Investigadores MEMOGAL
medRxiv 2023.12.05.23299557; doi: https://doi.org/10.1101/2023.12.05.23299557
Cost-Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study
José Seijas-Amigo, M. José Mauriz-Montero, Pedro Suarez-Artime, Mónica Gayoso-Rey, Francisco Reyes-Santías, Ana Estany-Gestal, Antonia Casas-Martínez, Lara González-Freire, Ana Rodriguez-Vazquez, Natalia Pérez-Rodriguez, Laura Villaverde-Piñeiro, Concepción Castro-Rubinos, Esther Espino-Faisán, Octavio Cordova-Arevalo, Moisés Rodríguez-Mañero, Alberto Cordero, José R. González-Juanatey, e Investigadores MEMOGAL
medRxiv 2023.12.05.23299557; doi: https://doi.org/10.1101/2023.12.05.23299557
Subject Area
Subject Areas
- Addiction Medicine (401)
- Allergy and Immunology (712)
- Anesthesia (204)
- Cardiovascular Medicine (2965)
- Dermatology (250)
- Emergency Medicine (444)
- Epidemiology (12781)
- Forensic Medicine (12)
- Gastroenterology (829)
- Genetic and Genomic Medicine (4609)
- Geriatric Medicine (423)
- Health Economics (732)
- Health Informatics (2939)
- Health Policy (1070)
- Hematology (391)
- HIV/AIDS (927)
- Medical Education (429)
- Medical Ethics (116)
- Nephrology (474)
- Neurology (4391)
- Nursing (237)
- Nutrition (646)
- Oncology (2284)
- Ophthalmology (650)
- Orthopedics (258)
- Otolaryngology (326)
- Pain Medicine (279)
- Palliative Medicine (83)
- Pathology (502)
- Pediatrics (1199)
- Primary Care Research (501)
- Public and Global Health (6980)
- Radiology and Imaging (1539)
- Respiratory Medicine (917)
- Rheumatology (443)
- Sports Medicine (385)
- Surgery (491)
- Toxicology (60)
- Transplantation (212)
- Urology (182)